Continuing challenges of sepsis research.
Crowther
M A
MA
Marshall
J C
JC
D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009102:Multiple Organ Failure / Q000209:etiology* / Q000517:prevention & control; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology
D000925:Anticoagulants; D011486:Protein C; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; D000990:Antithrombin III; D006493:Heparin; C421124:drotrecogin alfa activated